Author

Wanfen Tang

Institutions: Jinhua Central Hospital, Zhejiang University

Observed institutions: Jinhua Central Hospital, Zhejiang University

OpenAlex ID: A5157288697

Eribulin mesylate in combination with ivonescimab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer(EMIT): study protocol for a single-arm, multicenter clinical trial

2026 · Haiqi Lu, Xufei Wang, et al. · Frontiers in Immunology

Prognostic role of the naples prognostic score in advanced gastric cancer treated with immune checkpoint inhibitors: a retrospective multicenter study

2026 · Wanfen Tang, Lingfeng Ma, et al. · Scientific Reports

Works count: 2

Citation count:

H-index:

I10-index: